Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without Antibiotics

NEXT STORY
Roche Annual General Meeting 2019
PREV STORY
Silicon Valley TMS Now Offering Cutting Edge Mental Health Technology for Obsessive-Compulsive Disorder (OCD) in Northern California
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global WholeHealth Partners Corp. (GWHP) Announces It Now Offers the New FDA Cleared Fingerstick for Rapid COVID-19 Test Results in Minutes

author_avatar
NASDAQ Market News

Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2

VL-2397 appeared safe and well-tolerated with favorable pharmokinetic profile in healthy subjectsPhase 2 initiation ...

author_avatar
NASDAQ Market News

Worldwide Aminoglycosides Markets, 2019 to 2024: Expiry of Patent Exclusivity has Led to Large Scale Generic Manufacturing of Aminoglycosides, Particularly in the Developing Region of Asia-Pacific

author_avatar
NASDAQ Market News